Spain buy MDMA pills

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Spain buy MDMA pills

These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format. All countries. Topics A-Z. The content in this section is aimed at anyone involved in planning, implementing or making decisions about health and social responses. Best practice. We have developed a systemic approach that brings together the human networks, processes and scientific tools necessary for collecting, analysing and reporting on the many aspects of the European drugs phenomenon. Explore our wide range of publications, videos and infographics on the drugs problem and how Europe is responding to it. All publications. More events. More news. We are your source of drug-related expertise in Europe. We prepare and share independent, scientifically validated knowledge, alerts and recommendations. About the EUDA. MDMA is a synthetic drug chemically related to the amphetamines, but with somewhat different effects. In Europe, MDMA use has generally been associated with episodic patterns of consumption in the context of nightlife and entertainment settings. On this page, you can find the latest analysis of the drug situation for MDMA in Europe, including prevalence of use, seizures, price and purity and more. European Drug Report — home. The drug situation in Europe up to Drug supply, production and precursors. Synthetic stimulants. Heroin and other opioids. New psychoactive substances. Other drugs. Injecting drug use in Europe. Drug-related infectious diseases. Drug-induced deaths. Opioid agonist treatment. Harm reduction. Reported use of the drug appeared to decline temporarily during periods of social distancing during the early phases of the COVID pandemic. The currently available data would, however, suggest an overall relatively stable level of consumption but with national variations in the recent trends observed and the caveat that overall supply side indicators are suggestive of a slight recent decline in availability. About half of the European cities reporting wastewater analysis found an increase in MDMA residues between and , although in most other cities some decline was noted. Overall, available indicators suggest that MDMA production continues within Europe, both for domestic consumption and for export to non-EU markets. The information available is strongly suggestive that most MDMA production continues to be largely concentrated in or around the Netherlands. There are some signs of a reduction in the volume being manufactured in the most recent data. An important caveat here is that this information mostly covers the first years of the pandemic and needs to be interpreted with caution. In addition, while overall the average MDMA content of tablets and purity of powders remained stable in , a recent decrease in the MDMA content of ecstasy tablets was noted in some important source countries, most notably the Netherlands. With a typical MDMA content of to milligrams, the overall strength of tablets available on the retail marketplace still remains high by historical standards. It is difficult to interpret the more recent data with any certainty, but a possible decline in production volumes and some reductions noted in MDMA tablet content may indicate that producers have experienced greater problems sourcing precursor chemicals or that some producers may have switched to producing other substances, either because of market demand or because they are more profitable. It may also reflect a perceived consumer demand for lower-strength products. The use of MDMA is rarely cited as a reason for entering drug treatment in Europe but acute poisonings and deaths are sometimes associated with the consumption of this substance. The use of MDMA therefore continues to represent an important issue for prevention and harm reduction messaging and interventions. The availability of higher strength products potentially increases the risk of adverse health outcomes associated with the consumption of this substance. Interestingly, a decline in MDMA-related presentations by a quarter was observed in sentinel hospital emergency departments with data for and This data set, however, is difficult to interpret in respect to overall trends, as it is not nationally representative, has limited coverage and may reflect either changes in consumption or reporting during the pandemic. While it is again difficult to generalise due to limitations in national and European coverage, the available information from drug checking services suggests that MDMA products are generally less subject to adulteration than other illicit drugs they screened in This does occur however, as illustrated by the inclusion of synthetic cathinones in MDMA tablets observed on some occasions. These sorts of mixtures may also increase the risk to consumers of experiencing unexpected adverse effects and potential harm. This data explorer enables you to view our data on the prevalence of MDMA use by recall period and age range. You can access data by country by clicking on the map or selecting a country from the dropdown menu. Prevalence data presented here are based on general population surveys submitted to the EMCDDA by national focal points. For the latest data and detailed methodological information please see the Statistical Bulletin Prevalence of drug use. Graphics showing the most recent data for a country are based on studies carried out between and Mean daily amounts of MDMA in milligrams per population. Sampling was carried out over a week in March and April Show source tables. Back to list of tables. Homepage Quick links Quick links. GO Results hosted on duckduckgo. Main navigation Data Open related submenu Data. Latest data Prevalence of drug use Drug-induced deaths Infectious diseases Problem drug use Treatment demand Seizures of drugs Price, purity and potency. Drug use and prison Drug law offences Health and social responses Drug checking Hospital emergencies data Syringe residues data Wastewater analysis Data catalogue. Selected topics Alternatives to coercive sanctions Cannabis Cannabis policy Cocaine Darknet markets Drug checking Drug consumption facilities Drug markets Drug-related deaths Drug-related infectious diseases. Recently published Findings from a scoping literature…. Penalties at a glance. Frequently asked questions FAQ : drug…. FAQ: therapeutic use of psychedelic…. Viral hepatitis elimination barometer…. EU Drug Market: New psychoactive…. EU Drug Market: Drivers and facilitators. Statistical Bulletin home. Quick links Search news Subscribe newsletter for recent news Subscribe to news releases. This make take up to a minute. Once the PDF is ready it will appear in this tab. Sorry, the download of the PDF failed. Table of contents Search within the book. Search within the book Operator Any match. Exact term match only. No overall trend emerges from the data on MDMA use. Of the 11 European countries that undertook surveys since and provided confidence intervals, 1 reported higher estimates than their previous comparable survey, 9 reported stable estimates and 1 reported a decrease. Seizures of MDMA precursors increased to 2. The Netherlands, however, reported a lower average MDMA content of ecstasy tablets mg per tablet. MDMA market in Europe. Table 2. Prevalence of drug use in Europe, trends Country Country code Geographical scope Substance Recall period Age Austria AT National Table 3. Masaryk Water Resesrch institute, p. Table 4. Table 5. Table 6. Table 7. Table 8. Table 9. Table Main subject. Target audience. Publication type. European Drug Report main page. On this page. Forensic Toxicology Labs. Prevalence data presented here are based on general populaton surveys submitted to the EMCDDA by national focal points.

‘Pink cocaine’: The expensive and trendy drug is neither cocaine nor high quality

Spain buy MDMA pills

Joseph Janes does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment. A synthetic drug cocktail known as pink cocaine, has rapidly become a major concern in Spain, the UK and beyond. Earlier this month, Spanish authorities carried out their largest ever synthetic drug bust, seizing a large quantity of pink cocaine alongside more than a million ecstasy pills. The operation targeted drug networks across Ibiza and Malaga. This dangerous substance has been linked to a growing number of drug-related deaths. The unpredictable composition and rising popularity of pink cocaine have sparked calls from European drug harm reduction organisations for urgent action to address the risks it poses. MDMA , commonly known as ecstasy, is a stimulant with psychedelic properties while ketamine is a powerful anaesthetic which has sedative and hallucinogenic effects. Typically found in powder or pill form, pink cocaine is known for its vibrant colour, which is designed to enhance its visual appeal. The original psychedelic form of the drug dates to and was first synthesised by American biochemist, Alexander Shulgin. But the modern variant emerged around in Colombia and is a knock-off version. The drug gained popularity on the party scene in Latin America and has now spread to Europe. Users often expect a stimulant similar to cocaine, but the inclusion of ketamine can lead to serious health risks. Abuse of ketamine, which is widely available as a club drug, can lead to unconsciousness or dangerously laboured breathing. This in turn increases the potential dangers of pink cocaine. This mirrors the historical allure of drugs like cocaine and MDMA. It highlights a persistent trend where certain substances are glamourised despite their risks. Experts compare taking pink cocaine to playing Russian Roulette with substance use , underscoring the unpredictable and dangerous nature of pink cocaine. The drug has spread beyond Ibiza to the UK, and there is evidence that it has gained traction in Scotland , parts of Wales and England. Across the Atlantic, New York City has also seen a surge in its availability. Health officials across Europe are alarmed. Pink cocaine is difficult to detect through standard drug testing, particularly in Spain , where the current testing regime is not yet equipped to identify all its components. The legal response varies , with Spanish authorities working to curb its distribution. In the UK, pink cocaine falls under the Misuse of Drugs Act , which classifies drugs into three categories, class A, B, and C , based on their perceived harm. While pink cocaine itself may not be explicitly listed, the substances commonly found in it are controlled by the law. One of the most urgent needs highlighted by the rise of pink cocaine is for accessible drug-checking services. Drug-checking kits are an important harm-reduction tool for people looking to test the substances they intend to consume. These kits can help users identify unknown components, offering a layer of protection in a high-risk environment. My own work shows how vital such harm-reduction services are. Public awareness campaigns and support services are also an important part of reducing harm. The growing popularity of pink cocaine is a stark reminder of the ever-changing landscape of illicit drugs, where aesthetics, social media trends and risky behaviour can combine to create new threats. As pink cocaine continues to spread through Europe and beyond, it is crucial that authorities, health services and the public are equipped to deal with the risks it poses. Edition: Available editions Europe. Become an author Sign up as a reader Sign in. Pink cocaine is given its distinctive colour with food colouring or the addition of strawberry and other flavouring. Joseph Janes , Swansea University. Drugs Ketamine Narcotics Keep me on trend. Events More events.

Spain buy MDMA pills